Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
HIMS US​

Hims & Hers Health, Inc.(HIMS US)

$27.71-1.424.87%Ext:$27.76+0.050.18%(Market Closed · 00:00:02 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Hims & Hers Health, Inc. — Company Profile

Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.

Sector
Consumer Staples
Industry
Personal Care Products
Exchange
UN
CEO
Andrew Dudum
Headquarters
San Francisco, CA, US
IPO Date
Sep 13, 2019
Employees
2,442
Website
www.hims.com

Key Metrics

Price
$29.00
Market Cap
$6.47B
Revenue (TTM)
$608.10M
Net Income (TTM)
$-92115000.00
EPS (TTM)
-0.40
P/E (TTM)
-488.80
P/B (TTM)
14.50
Dividend Yield
0.00%
ROE (TTM)
-20.65%
ROA (TTM)
-4.06%
Operating Margin
-2.71%
Beta
2.53

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.

Website
www.hims.com
Location
San Francisco, CA, US
Phone415 851 0195
Employees2,442
CEOAndrew Dudum
Sector
Consumer Staples
Industry
Personal Care Products
IPO DateSep 13, 2019

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(1.3K)

Expand
  • 4Statement of changes in beneficial ownership15 Oct
  • 3Initial statement of beneficial ownership15 Oct
  • 144Boughton Soleil14 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers7 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 144Okupe Oluyemi1 Oct
  • 144Boughton Soleil30 Sep
  • 4Statement of changes in beneficial ownership23 Sep
  • 144Okupe Oluyemi22 Sep
  • 4Statement of changes in beneficial ownership18 Sep
  • 4Statement of changes in beneficial ownership17 Sep
  • 4Statement of changes in beneficial ownership17 Sep
  • 4Statement of changes in beneficial ownership17 Sep
  • 144Okupe Oluyemi17 Sep
  • 144Boughton Soleil16 Sep
  • 144Elshenawy Mohamed15 Sep
  • 144Chi Michael15 Sep
  • 4Statement of changes in beneficial ownership3 Sep
  • 144Boughton Soleil2 Sep

News

  • Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC23 Oct
  • Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC23 Oct
  • Hims & Hers Health, Inc. (HIMS) Declines More Than Market: Some Information for Investors23 Oct
  • HIMS Investor Alert: Hims & Hers Health, Inc. Stockholders with Large Losses Should Contact Robbins LLP About Leading the Class Action Lawsuit23 Oct
  • Hims & Hers Defends Subscription Practices And Privacy Disclosures Against Lawsuit23 Oct
  • HIMS DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS23 Oct
  • HIMS 10-DAY DEADLINE ALERT: Hims & Hers Health Facing Securities Class Action Lawsuit, Investors with Losses Encouraged to Contact Hagens Berman23 Oct
  • Kaplan Fox Reminds Hims & Hers Health, Inc. (NYSE: HIMS) Investors of an Approaching Securities Class Action Deadline on November 2, 202623 Oct
  • HIMS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Hims (HIMS) Investors of Securities Class Action Lawsuit Deadline on November 2, 202623 Oct
  • HIMS INVESTOR NOTICE: RGRD Law Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline23 Oct
  • Kaplan Fox Encourages Hims & Hers Health, Inc. (HIMS) Investors to Contact the Firm About Their Legal Rights Before November 2, 202623 Oct
  • Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm22 Oct
  • Hims & Hers Health (HIMS) Facing Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower22 Oct
  • Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS22 Oct
  • HIMS Deadline: HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit22 Oct
  • HIMS FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS22 Oct
  • INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS22 Oct
  • HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law22 Oct
  • Kaplan Fox Reminds Investors of Hims & Hers Health, Inc. (HIMS) of the Deadline to Seek Lead Plaintiff Status on November 2, 202622 Oct
  • Hims & Hers Health, Inc. (NYSE:HIMS) Stock Has Consensus Target Price of $32.4322 Oct

Mentions in Filings

  • … com. **Important Information About the Fund** The Defiance Daily Target 2X Long HIMS ETF (the “Fund”) seeks daily leveraged investment results of two times (200%) the daily percentage change in the share price of <strong>Hims & Hers Health</strong> Inc. (NYSE: HIMS) (the “Underlying Security” or “HIMS”). Because the Fund seeks daily leveraged investment results, it is very different from most other exchange-traded funds. It is also riskier than alternatives th …
    Tidal Trust IIHims & Hers Health, Inc.·497K - SUMMARY PROSPECTUS·Q3 26·28 Aug
  • #\*Hims & Hers Health, Inc. 116,752 3,162,812 \*ICON PLC 2,034 366,629 \*ICU Medical, Inc. 71,075 10,654,143 \*Ideaya Biosciences, Inc. 245,421 7,900,102 \*Immunovant, Inc. 18 468 \*Indivior Pharmaceuticals, Inc. 51,936 1,837,496 \*InfuSystem Holdings, Inc. 59,155 488,620 \*Innovage Holding Corp. 10,196 56,588 \*Innoviva, Inc. 228,918 4,578,360 \*Inogen, Inc. 87,228 514,645
    Dimensional ETF TrustHims & Hers Health, Inc.·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug
  • … NYSE:ZTS | $ | 59,313,032 | $ | 9,397,000 | $ | 4,132,000 | | $ | 9,440,783 | $ | 4,102,882 | | | Alkermes plc | | NASDAQGS:ALKS | $ | 4,131,367 | $ | 1,521,338 | $ | 481,895 | | $ | 1,470,965 | $ | 343,786 | | | <strong>Hims & Hers Health, Inc.</strong> | | NYSE:HIMS | $ | 7,277,729 | $ | 2,210,958 | $ | 293,192 | | $ | 2,346,611 | $ | 312,600 | | | Kiniksa Pharmaceuticals International, plc | | NASDAQGS:KNSA | $ | 2,757,798 | $ | 597,973 | $ | 74,707 | | $ | 67 …
    Zoar LtdHims & Hers Health, Inc.·F-4/A - Registration statement (business combination, foreign issuer, amendment)·Q3 27·21 Oct
  • … S CORP | (3,042 | ) | | (250,839 | ) | | (27,743 | ) | (7.4 | )% | | GENERAL MILLS INC | (3,852 | ) | | (179,519 | ) | | 13,865 | | 3.7 | % | | HERSHEY CO/THE | (3,287 | ) | | (557,581 | ) | | 12,141 | | 3.2 | % | | <strong>HIMS & HERS HEALTH</strong> INC | (4,254 | ) | | (193,374 | ) | | (49,624 | ) | (13.2 | )% | | INSPIRE MEDICAL SYSTEMS INC | (2,977 | ) | | (214,556 | ) | | 252,602 | | 67.1 | % | | INSULET CORP | (1,520 | ) | | (475,706 | ) | | (93,312 | ) | …
    SEG Partners Long/Short Equity FundHims & Hers Health, Inc.·486BPOS - Post-effective amendment (closed-end investment companies)·Q4 26·16 Oct
  • … NYSE:ZTS | $ | 59,313,032 | $ | 9,397,000 | $ | 4,132,000 | | $ | 9,440,783 | $ | 4,102,882 | | | Alkermes plc | | NASDAQGS:ALKS | $ | 4,131,367 | $ | 1,521,338 | $ | 481,895 | | $ | 1,470,965 | $ | 343,786 | | | <strong>Hims & Hers Health, Inc.</strong> | | NYSE:HIMS | $ | 7,277,729 | $ | 2,210,958 | $ | 293,192 | | $ | 2,346,611 | $ | 312,600 | | | Kiniksa Pharmaceuticals International, plc | | NASDAQGS:KNSA | $ | 2,757,798 | $ | 597,973 | $ | 74,707 | | $ | 67 …
    Zoar LtdHims & Hers Health, Inc.·F-4/A - Registration statement (business combination, foreign issuer, amendment)·Q3 27·2 Oct
  • … 72,221.32 | 950,143,799 | 66,878.69 | 879,856,146 | 3.26 | | America | stock | APPLE INC | Technology hardware and equipment | 18,940 | 47,412.46 | 897,992,030 | 45,751.75 | 866,538,308 | 3.21 | | America | stock | <strong>HIMS & HERS HEALTH</strong> INC | Healthcare equipment and services | 145,619 | 4,355.29 | 634,214,402 | 5,422.20 | 789,575,648 | 2.93 | | America | stock | UNITEDHEALTH GROUP INC | Healthcare equipment and services | 11,044 | 60,376.52 | 666, …
    三菱ＵＦＪアセットマネジメント株式会社Hims & Hers Health, Inc.·Prospectus - Amended Securities Registration Statement·14 Sep·13 Sep

Key Stats

Trading

Px/Chg 1D$29.00 / -1.02%
Avg Volume30.89M
Beta2.53
Mkt Cap6.47B
FD Mkt Cap6.56B

Float

Shrs Out/Float223.08M / 208.82M
Short Float0.29%
Days to Cover3.23
Stock Repurchased$0.00

Current Valuation

EV7.38B
EV/EBITDA308.40
EV/Sales3.11
P/B14.50
P/S2.73
FCF Yield0.82%
ROE-20.65%
ROA-4.06%
Current Ratio1.69

Estimates

P/E-488.80
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings34.74-37.49-100.1169.94311.58-70.23
Price / Sales6.874.672.705.9710.3910.64
Price / Book Value11.927.906.8518.4911.8714.50
Price / Free Cash Flow1,592.42-72.9050.1644.447,818.38121.99
ENTERPRISE VALUE METRICS
Enterprise Value5,597.42,420.92,270.58,605.47,310.97,379.1
Enterprise Value / Sales7.404.592.605.8311.8312.13
Enterprise Value / EBITDA12.68-39.54-113.88108.94200.60-92.70
Enterprise Value / EBIT70.47-35.24-77.09139.01398.35-72.66

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue71.4%271.9526.9872.01,476.52,347.6
Gross Income70.6%204.5408.7714.91,173.11,733.4
EBITDA—-111.0-61.2-19.979.0178.4
EBIT—-115.0-68.7-29.561.9123.9
Net Income—-107.7-65.7-23.5126.0128.4
EPS (Diluted)—-0.58-0.32-0.110.530.51
BALANCE SHEET
Cash & ST Inv23.6%247.3179.6221.0300.3577.5
Total Assets50.4%420.6366.3441.2707.52,154.7
Total Liabilities108.2%86.054.697.2230.81,613.8
Total Shareholder Equity12.8%334.6311.7344.0476.7540.9
CASH FLOW
Net Operating Cash Flow—-34.4-26.573.5251.1300.0
Cap Ex159.2%-5.0-7.2-26.5-52.8-226.0
Free Cash Flow—-39.4-33.847.0198.374.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)27.40
Basic Shares223.08
Market Cap6,112.4
Diluted Shares228.36
Fully Diluted Shares Outstanding228.36
Fully Diluted Market Cap6,257.0
+Consolidated Debt1,132.0
−In-the-Money Convertible Debt—
+Capital Leases157.9
+Operating Leases—
−Cash & Equivalents-222.3
−Short-term Investments-528.6
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value7,022.2

Segment data

Revenue

by Geography

  • United States94%
  • Non-us6%

Related companies

HCA Healthcare, Inc.

HCA US

Tenet Healthcare Corp

THC US

Universal Health Services Inc

UHS US

Surgery Partners, Inc.

SGRY US

Teladoc Health, Inc.

TDOC US

Community Health Systems Inc

CYH US

Auna S.a.

AUNA US

PHYHEALTH Corp

OSCI US

Basel Medical Group Ltd

BMGL US

Rennova Health, Inc.

RNVA US

Cardiff Lexington Corp

CDIX US